NEW YORK, March 12, 2018 /PRNewswire/ --
WallStEquities.com strives to bring the best free research to the investmentcommunity. Today we are offering reports on BAX, CFMS, XRAY, and HAE which can be accessed for free by signing up to www.wallstequities.com/registration. Research reports have been issued by WallStEquities.com on Baxter International Inc. (NYSE:
Deerfield, Illinois headquartered Baxter International Inc.'s shares recorded a trading volume of 2.44 million shares last Friday. The stock finished the trading session 1.58% higher at $68.89. The Company's shares have gained 5.10% in the last month, 8.11% over the previous three months, and 32.15% over the past year. The stock is trading above its 50-day and 200-day moving averages by 1.65% and 8.23%, respectively. Furthermore, shares of Baxter, which provides a portfolio of healthcare products, have a Relative Strength Index (RSI) of 57.37.
On February 20th, 2018, Baxter's Board of Directors has declared a quarterly cash dividend of $0.16 per share of common stock, payable on April 02nd, 2018, to stockholders of record as of March 02nd, 2018. The indicated annual dividend rate is $0.64 per share of common stock. The Board also has approved a $1.5 billion increase in authorization for the Company's existing share repurchase plan. Get the full research report on BAX for free by clicking below at: www.wallstequities.com/registration/?symbol=BAX
On Friday, Bedford, Massachusetts headquartered ConforMIS Inc.'s stock ended the session 3.36% lower at $1.44. A total volume of 317,950 shares was traded. The Company's shares have gained 14.29% in the last month. The stock is trading 21.02% below its 50-day moving average. Moreover, shares of ConforMIS, which develops, manufactures, and sells customized joint replacement implants, have an RSI of 42.48.
On March 01st, 2018, ConforMIS announced that the Orthopaedic Data Evaluation Panel in the United Kingdom awarded the ConforMIS iTotal CR knee replacement system a "3A" rating. The 3A rating is based on strong evidence of implant performance over three years, including low revision rates as indicated in the United Kingdom's National Joint Registry. The free technical report on CFMS can be accessed at: www.wallstequities.com/registration/?symbol=CFMS
York, Pennsylvania headquartered DENTSPLY SIRONA Inc.'s stock ended the day 1.26% higher at $57.67 with a total trading volume of 2.03 million shares. The stock is trading 5.25% below their 50-day moving average. Shares of the Company, which designs, develops, manufactures, and markets various dental and oral health products, and other consumable healthcare products primarily for the professional dental market worldwide, have an RSI of 46.83.
On February 14th, 2018, DENTSPLY SIRONA announced that its Board of Directors declared a quarterly cash dividend of $0.0875 per share of common stock, an indicated annual rate of $0.35 per share. The dividend is payable on April 13th, 2018, to holders of record on March 29th, 2018.
On March 08th, 2018, research firm Barclays initiated an 'Equal Weight' rating on the Company's stock, with a target price of $62 per share. Sign up for free on Wall St. Equities and claim the latest report on XRAY at: www.wallstequities.com/registration/?symbol=XRAY
Shares in Braintree, Massachusetts headquartered Haemonetics Corp. recorded a trading volume of 310,167 shares. The stock ended Friday's session 1.11% higher at $73.96. The Company's shares have gained 6.07% in the last month, 29.50% over the previous three months, and 91.95% over the past year. The stock is trading above its 50-day and 200-day moving averages by 11.50% and 45.63%, respectively. Furthermore, shares of Haemonetics, which provides hematology products and solutions, have an RSI of 72.32. See the free research coverage on HAE at: www.wallstequities.com/registration/?symbol=HAE
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit https://wallstequities.com/legal-disclaimer/
For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: firstname.lastname@example.org Phone number: +21-32-044-483Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
View original content:http://www.prnewswire.com/news-releases/quotidian-technical-highlights-on-selected-medical-supplies-stocks----baxter-conformis-dentsply-sirona-and-haemonetics-300612131.html
SOURCE Wall St. Equities
Subscribe to our Free Newsletters!